Editorial Comment
October 2013
in “
Urology
”
TLDR More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
The editorial discussed the increasing trend in using medication to manage benign prostatic hyperplasia (BPH) in men, highlighting several key factors contributing to this shift. The FDA approvals of tamsulosin and dutasteride, along with significant studies like the Medical Therapy of Prostatic Symptoms trial and research by Kaplan et al., were pivotal in this trend. Despite no proven superiority of dutasteride over finasteride, it became the most commonly prescribed 5 alpha reductase inhibitor, influenced by FDA's approval of direct-to-consumer marketing. This shift raised concerns about adherence to evidence-based medicine.